Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Docusate sodium
Cat. No.:
OB0225LY-0091
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Docusate sodium is a surfactant. It's associated with constipation.
Synonym:
Aerosol OT; Dioctyl sulfosuccinate sodium salt; Bis(2-ethylhexyl) sulfosuccinate sodium salt; Constonate; 577-11-7; Sodium sulfodi-(2-ethylhexyl)-sulfosuccinate
CAS No.:
577-11-7
Compound CID:
23673837
Formula:
C20H37NaO7S
Formula Weight:
444.56
Specification
Relative Density:
1.1 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Docusate sodium can be used to enhance drug bioavailability.
Library Information
Targets:
Opioid receptor
Pathways:
Endocrinology/Hormones; GPCR/G protein; Neuronal signaling; Microbiology/Virology
Plate Number:
AOCL-2
Plate Location:
b4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
60 mg/mL; 134.96 mM
Water Max Solubility:
15 mg/mL; 33.7 mM
Ethanol Max Solubility:
82 mg/mL; 184.5 mM
